On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...

In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a ...

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes ...